Answers are grounded in this paper and cite their sources.
Review outlines neuroprotective properties of mesenchymal stem cells in multiple sclerosis, suggesting therapeutic potential.
In multiple sclerosis (MS), there is a great need for treatment with the ability to suppress compartmentalized inflammation within the central nervous system (CNS) and to promote remyelination and regeneration. Mesenchymal stem cells (MSCs) represent a promising therapeutic option, as they have been shown to migrate to the site of CNS injury and exert neuroprotective properties, including immunomodulation, neurotrophic factor secretion, and endogenous neural stem cell stimulation. This review summarizes the current understanding of the underlying neuroprotective mechanisms and discusses the translation of MSC transplantation and their derivatives from pre-clinical demyelinating models to clinical trials with MS patients.
No takes yet. Share an insight, caveat, or question.
Gavasso et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: